NEUROENDOCRINE TUMORS

Cabozantinib Versus Placebo in Patients with Advanced Neuroendocrine Tumors After Progression on Prior Therapy (CABINET)

Clinical Trial Website: NCT03375320 Current Status: Recruiting by invitation only

Design: This randomized phase III trial studies cabozantinib to see how well it works compared with placebo in treating patients with neuroendocrine or carcinoid tumors that have spread to other places in the body (advanced). Cabozantinib is a chemotherapy drug known as a tyrosine kinase inhibitor, and it targets specific tyrosine kinase receptors, that when blocked, may slow tumor growth.

Key Inclusion:

- Patients must have biopsy proven neuroendocrine pancreatic tumors
- Patients must have measurable disease by CT or MRI scan
- Patients must have had at least one previous treatment with an FDA-approved line of therapy

Key Exclusion:

- Prior treatment with cabozantinib
- Concurrent uncontrolled illnesses.

Principal Investigator: Hanna Sanoff, MD

Coordinator: Brian Burgess
Phone: (984) 974-8772

PROmoting CLinicAl Trlal EngageMent for Pancreatic Cancer App Study (PROCLAIM Study)

Clinical Trial Website: NCT06252545 Current Status: Recruiting

Description: This two-part, randomized trial seeks to identify and address barriers to enrollment of Black patients in pancreatic cancer clinical trials by conducting interviews and creating a culturally-informed mobile health application to promote participation.

Key Inclusion:

- Patients at least 18 years old
- Patients must identify as Black
- Have newly diagnosed or progressive pancreatic cancer
- Have access to a mobile device

Key Exclusion:

- Inability to read and speak English
- Dementia altered mental status or a psychiatric condition prohibiting informed consent
- Active participation in a therapeutic clinical trial

Principal Investigator: Jen Jen Yeh, MD

Coordinator: Brent Henderson
Phone: 919-966-7706